Lung Cancer Highlights

Lung Cancer Highlights Thomas J. Lynch, Jr Oncologist 2000; 5: 274-279, Author Information and Disclosures Target Audience: Physicians who wish to advance their current knowledge of clinical cancer medicine in lung cancer and are involved in providing patient care in a cancer care environment. Method of Physician Participation: Read course materials, complete course quiz and evaluation form (optional). Learning Objectives After completing this course, the reader should be able to: Know the current status of chemotherapy in the treatment of advanced non-small cell lung cancer. Understand the rationale behind the potential efficacy of rHumAb VEGF (a recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) and its toxicity. Know the current chemotherapy approaches to extensive stage small cell lung cancer. The NIH/FAES designates this educational activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CME Activity Information Accreditation CME Instructions For Credit Privacy Statement Hardware/Software Requirements Release Date: Jul. 10, 2002 Most Recent Review: June 10, 2005* Most Recent Update: Jul. 10, 2002 Date Credit Expires: Apr. 10, 2007 Time to Complete: 1 hour Medium: Internet Online *Click here to learn more about our review process.